Akero Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation
Non-cash lease expense
Net amortization of premiums and discounts on marketable securities
Amortization of debt issuance costs and discount
Fair value change in warrant liability
Write-off of deferred offering costs
Unrealized foreign exchange gain and loss
Acquired in-process research and development expense
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other current liabilities
Other liabilities
Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of short-term and long-term marketable securities
Proceeds from sales of short-term marketable securities
Proceeds from maturities of short-term marketable securities
Purchase of property and equipment
Purchase of in-process research and development
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of stock options
Proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases
Proceeds from the disgorgement of stockholders' short-swing profits, net
Proceeds from the issuance of common stock in a follow-on public offering, net of underwriting costs
Proceeds from the issuance of common in a follow-on public offering
Proceeds from the issuance of common stock in a follow-on public offering
Proceeds from the issuance of common stock pursuant to the ATM offering
Proceeds from the issuance of common stock pursuant to registered direct offering
Proceeds from the issuance of common stock pursuant to private offering
Proceeds from loan payable
Payment of loan payable issuance costs
Payment of follow-on public offering issuance costs
Payment of private equity offering costs
Payment of debt and equity issuance costs
Payment of deferred offering costs
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at the beginning of the period
Cash, cash equivalents and restricted cash at the end of the period
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest
NON-CASH INVESTING AND FINANCING INFORMATION:
Right of use asset obtained in exchange for operating lease liability
Change in net unrealizable gain on marketable securities
Remeasurement of right of use asset and operating lease liability
Warrant liability costs reclassified to additional paid-in equity on vested warrants issued
Debt and equity issuance costs included in accounts payable and accrued expenses and other current liabilities
Equity issuance costs included in accounts payable and accrued expenses and other current liabilities
Deferred offering costs reclassified to additional paid-in equity
Deferred offering costs included in accounts payable and accrued expenses and other current liabilities

Comments